Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
University of California, San Francisco · University of California San Diego · +5 more institutions
Abstract
The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established.
We randomly assigned 10,101 postmenopausal women (mean age, 67.5 years) with CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years. The two primary outcomes were coronary events (i.e., death from coronary causes, myocardial infarction, or hospitalization for an acute coronary syndrome) and invasive breast cancer.
Citation impact
- FWCI
- 54.63
- Percentile
- 100%
- References
- 32
Authors
8- EBElizabeth Barrett‐ConnorCorresponding
University of California, San Francisco, University of California San Diego
- LMLori Mosca
University of California, San Francisco, Columbia University
- PCPeter Collins
University of California, San Francisco, Lung Institute
- MJMary Jane Geiger
Eli Lilly (United States), University of California, San Francisco
- DGDeborah Grady
San Francisco VA Medical Center
Topics & keywords
- Medicine
- Raloxifene
- Breast cancer
- Postmenopausal women
- Oncology
- Internal medicine
- Menopause
- Gynecology
- Good health and well-being